

FRAG1, when fused to FGFR2, leads to a transformed phenotype when transfected into cells and enhanced levels of phosphorylation/activation of FGFR2. The FGFR2-FRAG1 fusion protein was isolated from an osteosarcoma. Products derived from the FRAG1 cDNA, protein or antibodies which recognize the FRAG1 antigen are likely to be useful as diagnostics, therapeutics and research reagents.

This work has appeared, in part, in Lorenzi, MV, et al. "FRAG1, a gene that potentially activates fibroblast growth factor receptor by C-terminal fusion through chromosomal rearrangement" PNAS, USA 93(17): 8956-61 (Aug. 20, 1996).

Spontaneous Breathing Apparatus and Method

Theodor Kolobow (NHLBI)
Serial No. 08/933,003 filed 18 Sep 1997.
Licensing Contact: Girish Barua; 301/496-7056 ext. 263; e-mail: gb18t@nih.gov

A novel assisted breathing system and method has been developed to greatly decrease/eliminate work of breathing, and is under the total control of a patient.

The system includes a minitracheostomy tube, a reverse thrust gas insufflation catheter introduced through a special minitracheostomy tube to deliver well humidified air/oxygen to near the carina, and a threshold valve to limit airway plateau pressure. Inspiration is effected through spontaneous closing of the glottic opening, while expiration follows opening of the glottis. Such breathing is under the exclusive, spontaneous control of a patient to determine respiratory rate and tidal volumes. Lung inflation is hence passive, and accounts for the greatly decreased (even zero) work of breathing. Speech, cough and swallowing remain unimpeded.

Dated: August 16, 1999.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 99-21706 Filed 8-19-99; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Neurological Disorders and Stroke; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Advisory Neurological Disorders and Stroke Council.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosures of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Advisory Neurological Disorders and Stroke Council.

Date: September 23-24, 1999.

Open: September 23, 1999, 8:30 AM to 3 PM.

Agenda: Report by the Director, NINDS; Report by the Associate Director for Extramural Research; and other administrative and program developments.

Place: National Institutes of Health, Building 31, Conference Room 6, 31 Center Drive, Bethesda, MD 20892.

Closed: September 23, 1999, 3 PM to 5 PM.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Building 31, Conference Room 6, 31 Center Drive, Bethesda, MD 20892.

Closed: September 24, 1999, 8:30 AM to 12 PM.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Building 31, Conference Room 6, 31 Center Drive, Bethesda, MD 20892.

Contact Person: Constance W. Atwell, Associate Director for Extramural Research, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Neuroscience Center, 6001 Executive Blvd., Suite 3309, MSC 9531, Bethesda, MD 20892-9531, (301) 496-9248.

(Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS)

Dated: August 13, 1999.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 99-21701 Filed 8-19-99; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel—Vancomycin Resistant S. aureus in Dialysis Patients.

Date: August 30, 1999.

Time: 9:30 am to 10:30 am.

Agenda: To review and evaluate grant applications.

Place: NIAID, NIH (Room 2148), 6700-B Rockledge Drive, MSC 7610, Bethesda, MD 20892-7610 (Telephone Conference Call).

Contact Person: Dianne E. Tingley, Scientific Review Administrator, Scientific Review Program, Division of Extramural Activities, NIAID, NIH, Room 2220, 6700-B Rockledge Drive, MSC 7610, Bethesda, MD 20892-7610, 301-496-2550.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: August 13, 1999.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy, NIH.

[FR Doc. 99-21702 Filed 8-19-99; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Dental and Craniofacial Research; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as